Xoma | XOMA - Equity Capital And Reserves


Xoma reported $87.94M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Agenus USD -271.11M 3.03M Dec/2025
Agios Pharmaceuticals USD 1.19B 91.22M Dec/2025
Ardelyx USD 166.95M 12.67M Dec/2025
aTyr Pharma USD -24.12M 104.35M Dec/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Celldex Therapeutics USD 527.16M 71.2M Dec/2025
Curis USD 5.46M 19.45M Dec/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Emergent BioSolutions USD 649.3M 47.9M Dec/2023
Incyte USD 5.17B 516.28M Dec/2025
MacroGenics USD 55.59M 11.41M Dec/2025
Novartis USD 46.13B 1.38B Dec/2025
Novartis USD 46.13B 1.8B Dec/2025
Pfizer USD 92.8B 4.11B Sep/2025
Prothena USD 280.47M 14.51M Dec/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Xoma USD 87.94M 15.5M Sep/2025